Clinical Trials in Arizona

Showing 2161-2180 of 8,032 trials

A Study to Assess the Bioequivalence of Ustekinumab by Two Different Injection Devices in Healthy Participants

NCT04816513

The purpose of this study is to evaluate the pharmacokinetic (PK) and bioequivalence (BE) of ustekinumab administered by a single subcutaneous (SC) injection with Device 1 or Device 2 in healthy participants.

Healthy

Janssen Research & Development, LLC300 participantsStarted Apr 2021

Tempe, Arizona, United States • Lincoln, Nebraska, United States • Salt Lake City, Utah, United States

Active Not RecruitingPhase 235 miles

MTT for Children With ASD Who Have Gastrointestinal Disorders

NCT04182633

The investigators propose to investigate Microbiota Transfer Therapy (MTT) for treating children with Autism Spectrum Disorder (ASD) and gastrointestinal problems (primarily constipation and/or diarrhea). MTT involves a combination of 10 days of oral vancomycin (an antibiotic to kill pathogenic bacteria), followed by a bowel cleanse, followed by 12 weeks of Fecal Microbiota (FM).

Autism Spectrum DisorderGastro-Intestinal DisorderConstipation+1 more

Arizona State University50 participantsStarted Nov 2019

Tempe, Arizona, United States

RECRUITING42 miles

Pulmonary Hemodynamics During Exercise - Research Network

NCT03954574

The purpose of this Clinical Research Collaboration is to investigate the prognostic implications of pulmonary hemodynamics during exercise based on a large scale multi-centre approach by using retrospective and prospective analysis of hemodynamic data.

Pulmonary Circulation Diseases

Medical University of Graz1,500 participantsStarted Dec 2018

Phoenix, Arizona, United States • Los Angeles, California, United States • Baltimore, Maryland, United States +29 more locations

A Study to Assess the Bioequivalence of Ustekinumab by Two Different Injection Devices in Healthy Participants

MTT for Children With ASD Who Have Gastrointestinal Disorders

Pulmonary Hemodynamics During Exercise - Research Network

Find Trials by Condition in Arizona

Open-Label Extension: Tolerability and Effects of ALK-001 on Stargardt Disease (TEASE)

A Global Study to Assess the Effects of MEDI4736 (Durvalumab) in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer

Lay Health Worker Expanded Intervention in Community Oncology Practices

A Study of Apalutamide (Adjuvant Treatment) and Androgen Deprivation Therapy (ADT) in Participants Who Have Undergone Radical Prostatectomy (RP) for Non-metastatic Prostate Cancer and Who Are at High Risk for Metastases

A Study of Seltorexant as Adjunctive Therapy to Antidepressants in Adult and Elderly Participants With Major Depressive Disorder With Insomnia Symptoms Who Have Responded Inadequately to Antidepressant and Long-term Safety Extension Treatment With Seltorexant

A Study of Ustekinumab in Participants With Active Systemic Lupus Erythematosus

A Study of Esketamine Nasal Spray, Administered as Monotherapy, in Adult Participants With Treatment-resistant Depression

A Study to Evaluate the Efficacy and Safety of JNJ-42847922 as Adjunctive Therapy to Antidepressants in Adult Participants With Major Depressive Disorder Who Have Responded Inadequately to Antidepressant Therapy

An Efficacy and Safety Study of Sirukumab in Participants With Major Depressive Disorder

ShOrt neCK AAA RAndomized Trial - ESAR and FEVAR: SOCRATES

A Study to Evaluate the Efficacy and Safety of VIB4920 in Participants With Sjögren's Syndrome

A Study to Evaluate the Safety and Efficacy of Intranasal Esketamine in Treatment-resistant Depression

APX005M and Doxorubicin in Advanced Sarcoma

Promoting Early Intervention Timing and Attention to Language

A Phase 1/2, First-in-Human Dose Escalation/Expansion Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of a Subretinal Injection of SB-007 in Subjects With Stargardt Disease (STGD1)

A Study of JNJ-73763989 + Nucleos(t)Ide Analog in Participants Co-Infected With Hepatitis B and Hepatitis D Virus

Study of Dabrafenib+Trametinib in the Adjuvant Treatment of Stage III BRAF V600+ Melanoma After Complete Resection to Evaluate the Impact on Pyrexia Related Outcomes